NEULANDLAB - Technical Analysis with Chart Patterns & Indicators
Back to ListTechnical Rating: 4.4
| Stock Code | NEULANDLAB | Market Cap | 21,357 Cr. | Current Price | 16,634 ₹ | High / Low | 19,748 ₹ |
| Stock P/E | 58.8 | Book Value | 1,454 ₹ | Dividend Yield | 0.07 % | ROCE | 26.6 % |
| ROE | 21.5 % | Face Value | 10.0 ₹ | DMA 50 | 15,185 ₹ | DMA 200 | 14,366 ₹ |
| Chg in FII Hold | -0.44 % | Chg in DII Hold | 1.12 % | PAT Qtr | 213 Cr. | PAT Prev Qtr | 40.4 Cr. |
| RSI | 60.5 | MACD | 612 | Volume | 67,144 | Avg Vol 1Wk | 52,053 |
| Low price | 11,011 ₹ | High price | 19,748 ₹ | PEG Ratio | 1.94 | Debt to equity | 0.16 |
| 52w Index | 64.4 % | Qtr Profit Var | 666 % | EPS | 283 ₹ | Industry PE | 30.5 |
📈 Chart & Trend: NEULANDLAB is trading at 16,634 ₹, well above its 50 DMA (15,185 ₹) and 200 DMA (14,366 ₹), confirming strong bullish momentum. Support lies at 16,400–16,500 ₹, with resistance around 17,200–17,300 ₹.
🔎 Momentum Signals: RSI at 60.5 indicates healthy bullish momentum but nearing overbought territory. MACD at 612 shows a strong positive crossover, reinforcing upward bias. Entry zone: 16,400–16,500 ₹. Exit zone: 17,200–17,300 ₹.
📊 Volume Trends: Current volume (67,144) is above the 1-week average (52,053), reflecting strong participation and accumulation interest.
📉 Bollinger Bands: Bands are wide, suggesting volatility expansion and trending momentum.
📌 Trend Status: The stock is in a strong uptrend supported by technical signals and earnings momentum.
Positive
- Trading above both 50 DMA and 200 DMA confirms bullish technical strength.
- Strong ROCE (26.6%) and ROE (21.5%) highlight efficient capital use.
- EPS of 283 ₹ supports profitability.
- Quarterly PAT surged (213 Cr. vs 40.4 Cr.), showing robust earnings growth.
- DII holdings increased (+1.12%), reflecting domestic institutional support.
Limitation
- High P/E (58.8) compared to industry average (30.5) indicates premium valuation.
- PEG ratio of 1.94 suggests valuation risk relative to growth.
- RSI above 60 signals limited upside before overbought territory.
- FII holdings declined (-0.44%), showing reduced foreign investor confidence.
Company Negative News
- Valuation concerns due to high P/E and PEG ratio.
- Foreign institutional investors reduced exposure.
Company Positive News
- Quarterly profit variation (+666%) highlights strong earnings momentum.
- DII inflows (+1.12%) reflect strong domestic institutional support.
Industry
- Industry PE at 30.5 suggests sector is moderately valued compared to NEULANDLAB’s premium valuation.
- Pharmaceutical sector benefiting from global demand and export opportunities.
Conclusion
NEULANDLAB is in a strong uptrend, trading above key moving averages with bullish RSI and MACD signals. Fundamentals remain supportive with robust earnings growth and institutional confidence, though stretched valuations and overbought signals limit immediate upside. Best suited for entry near 16,400–16,500 ₹ with profit booking around 17,200–17,300 ₹.
NEULANDLAB is clearly in a strong uptrend with momentum-driven signals. To broaden the view, I can extend this into a peer benchmarking analysis or a sector overlay comparison to highlight its position against other pharmaceutical peers.